biotech
biotech Articles
Viamet Pharmaceuticals intends to price more than 5 million shares within the range of $14 to $16 per share for an initial public offering valued up to almost $105 million.
Published:
Last Updated:
Infectious diseases always have been a hot topic in biotech, but over the past half decade more capital has been drawn into the space.
Published:
Last Updated:
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) has only been public for a few weeks, but the analysts from its underwriting syndicate have issued massive upside calls. The driving force behind Aeglea is...
Published:
Last Updated:
With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls by the week's end.
Published:
Last Updated:
Gilead Sciences Inc. (NASDAQ: GILD) reported first-quarter financial results after the markets closed on Thursday. The company had $3.03 in earnings per share (EPS) on $7.79 billion in revenue...
Published:
Last Updated:
In a filing with the SEC, Oncobiologics said it expects to price 5 million shares within the range of $11 to $13 per share.
Published:
Last Updated:
The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
Typically each year, the first quarter is the slowest for biotech stocks. SunTrust Robinson Humphrey has four stocks rated Buy that should come in fine when numbers are released.
Published:
Last Updated:
Sarepta Therapeutics shares got crushed on Thursday and then exploded on Friday following the FDA view on its Duchenne muscular dystrophy treatment.
Published:
Last Updated:
BioMarin Pharmaceutical is ready to break above the $1 billion revenue barrier in 2016, a feat that marks a major hurdle for many biotech and emerging pharmaceutical companies.
Published:
Last Updated:
Cara Therapeutics saw its shares jump early on Wednesday after it announced that it has received notice from the FDA that it has removed the clinical hold on its adaptive Phase 3 trial of I.V. CR845...
Published:
Last Updated:
Gemphire Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
New research from Jefferies highlights this week's top growth stock picks, and there is a clear bias for some top biotech and pharmaceutical stocks — and with good reason. They are cheap and have...
Published:
Last Updated:
Shares of Clovis Oncology dropped after the FDA Oncologic Drugs Advisory Committee voted against its lung cancer drug.
Published:
Last Updated:
PTC Therapeutics saw its shares jump late Friday morning on positive news on its nonsense mutation Duchenne muscular dystrophy treatment.
Published:
Last Updated: